PresentationAll right. Great. Welcome, everybody. I'm Casey Woodring from the Life Science Tools and Diagnostics team here at JPMorgan. Welcome to our conference. Pleased to be joined by Tempus AI, CEO, Eric Lefkofsky. We'll go through the corporate presentation, then leave time for the Q&A afterwards. Eric, all yours.Eric LefkofskyCo-Founder, CEO, President & Chairman Thank you. Welcome. There's seats up here -- for people in the back, but by all means, feel free to walk up. So I'll try to give you a littl ...

Tempus AI (NasdaqGS:TEM) FY Conference January 12, 2026 04:30 PM ET Speaker0All right, great. Welcome, everybody. I'm Casey Woodring from the Life Science Tools and Diagnostics team here at J.P. Morgan. Welcome to our conference. Pleased to be joined by Tempus AI CEO Eric Lefkofsky. We'll go through the corporate presentation, then leave time for the Q&A afterwards. Eric, all yours.Speaker2Thank you. Welcome. I don't have seats up here. I'm going to have people in the back, but my homies, feel free to walk ...

1 44th Annual J.P. Morgan Healthcare Conference JANUARY 2026 ERIC LEFKOFSKY Disclaimer This presentation contains forward-looking statements that reflect Tempus AI, Inc.'s (the "Company" or "Tempus") current expectations and projections with respect to, among other things, its preliminary, unaudited financial results for the fourth quarter and full year 2025, its financial condition, results of operations, plans, objectives, future performance and business. Forward-looking statements include all statements ...

Key Takeaways TEM stock gained 105% in a year as Genomics and Data results exceeded expectations for 2025. Tempus earned multiple FDA 510(k) clearances, expanding its AI-based diagnostics and imaging portfolio. TEM delivered positive adjusted EBITDA, though GAAP losses continue due to compensation and amortization. Tempus AI (TEM) stock has delivered a remarkable 105% gain over the past year, driven by strong performance across both its Genomics and Data segments, surpassing initial expectations for 2025. A ...

Tempus AI stock remains in a bear market after crashing by 36% from its highest point in September last year. It has slumped to $66, with its market capitalization slumping from $17.8 billion in Octob... ...

数据与应用业务营收约1亿美元，同比增长约25%(若剔除2024年第四季度阿斯利康认股权证的影响，则 洞察业务增长约68%)。 Tempus创始人兼首席执行官Eric Lefkofsky表示："2025年对Tempus来说是卓越的一年，我们两条产品线 的表现均超出了年初预期。在诊断业务中，我们的基因组学(肿瘤)产品检测量同比增长已连续三个季度 加速，达到了多年来最高的单位增长率。 我们的数据与应用业务表现更为强劲，第四季度营收创下约1亿美元的纪录，全年增长约31%，其中数 据授权业务增长约38%。我们以异常强劲的态势进入2026年，两大主营业务增长均在加速，并释放出我 们平台固有的财务杠杆效应。随着AI成为我们所有产品的催化剂，我们对2026年充满期待。" 致力于推动人工智能应用于精准医疗的领先技术公司Tempus AI(TEM.US)公布了截至2025年12月31日的 第四季度及全年初步未经审计的业绩摘要。报告称，其2025年营收约为12.7亿美元，实现同比增长约 83%(其中有机增长约30%，不含Ambry Genetics业务贡献)。截至发稿，该股盘前涨12%。 数据显示，该公司2025年度诊断业务营收约 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2026 Tempus AI, Inc. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 600 West Chicago Avenue Suite 510 Chicago, Illinois 60654 (Address of Principal Executive Offices) (Zip Code) (Commission File Number) Nevada 001-42130 47-49033 ...

U.S. stock futures declined on Monday after a positive close on Friday. Futures of major benchmark indices were trading lower.Tensions flared up at the Federal Reserve after the Chair Jerome Powell said on Sunday that the Department of Justice had threatened the central bank with "criminal indictment" over his testimony before Congress, relating to its building renovation costs. This marks a major escalation in tensions between President Donald Trump and the central bank. On Friday, nonfarm payrolls increas ...

Core Insights - Tempus AI, Inc. has achieved a record Total Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025 [1] - The company signed data agreements with over 70 customers in 2025, including major pharmaceutical companies [1] Company Overview - Tempus AI, Inc. is a technology company focused on advancing precision medicine through the adoption of artificial intelligence [1] - The company operates in the healthcare technology sector, specifically targeting the pharmaceutical industry [1] Customer Engagement - The customer base includes both large and mid-sized pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, and Boehringer Ingelheim [1] - The agreements signed in 2025 reflect a strong demand for Tempus's AI-driven solutions in the pharmaceutical sector [1]

"2025 was an exceptional year for Tempus with the strength of both of our product lines exceeding our initial expectations for the year,†said Eric Lefkofsky, Founder and CEO of Tempus. "Within Diagnostics, year- over-year volume growth of our genomics (oncology) offering accelerated for the third consecutive quarter hitting the highest unit growth rate we have seen in years. Our Data and Application business is performing even better with record revenue of ~$100 million in the fourth quarter, achieving full ...